Logotype for Cellectar Biosciences Inc

Cellectar Biosciences (CLRB) investor relations material

Cellectar Biosciences Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cellectar Biosciences Inc
Q2 2025 earnings summary14 Aug, 2025

Executive summary

  • Advanced iopofosine I 131 toward FDA accelerated approval for Waldenstrom's macroglobulinemia, with confirmatory study and NDA submission planned, pending funding and partnerships.

  • Achieved FDA Breakthrough Therapy and EMA PRIME designations for iopofosine I 131, with ongoing regulatory engagement in the US and Europe.

  • Expanded radiopharmaceutical pipeline, with CLR125 and CLR225 advancing toward Phase I trials for solid tumors, including triple negative breast cancer and pancreatic cancer.

  • Entered long-term isotope supply agreements to support clinical and future commercial needs.

  • Exploring strategic alternatives, including partnerships or transactions, to advance the platform and secure funding.

Financial highlights

  • Ended Q2 2025 with $11M in cash and equivalents, plus $5.8M raised in July 2025, supporting operations into Q2 2026.

  • R&D expenses for Q2 2025 were $2.4M, down 67% year-over-year, mainly due to completion of patient enrollment and lower clinical costs.

  • G&A expenses for Q2 2025 were $3.6M, down 43–44% year-over-year, reflecting reduced pre-commercialization and personnel costs.

  • Net loss for Q2 2025 was $5.4M ($3.39 per share), compared to $0.9M ($0.77 per share) in Q2 2024, mainly due to non-cash warrant activity.

  • Used $14.5M in cash for operations in the first half of 2025.

Outlook and guidance

  • Cash runway, including recent financings, expected to fund operations into Q2 2026.

  • NDA submission for iopofosine I 131 and initiation of confirmatory trial contingent on securing additional funding or partnerships.

  • CLR125 and CLR225 Phase I trials for solid tumors planned for late 2025 or early 2026, pending funding.

  • Management expects continued operating losses and negative cash flow until product candidates are commercialized.

  • Decision on EMA conditional marketing authorization submission for iopofosine I 131 expected late Q3 or early Q4 2025.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cellectar Biosciences earnings date

Logotype for Cellectar Biosciences Inc
Q3 202517 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cellectar Biosciences earnings date

Logotype for Cellectar Biosciences Inc
Q3 202517 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage